Lexicon Pharmaceuticals Inc. Common Stock (LXRX)
Stock · NASDAQ · Health Care
$1.52as of 10/16/2026
Price chart
Active signals
LXRX Signal Track Record
How signals performed across all stocks →What LXRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +5.1% | 53% | September 28, 2026 |
| Bollinger Band Breakout | 30 | -7.7% | 37% | August 4, 2026 |
| Bollinger Band Breakdown | 18 | -0.1% | 50% | September 24, 2026 |
| 200-Day Moving Average TouchActive now | 18 | +3.0% | 56% | June 25, 2025 |
| Any 20-session window (baseline) | 0.0% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotaglifloz…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 81
- Website
- www.lexpharma.com/
Fundamentals
- 1-day range
- $1.62$1.68
- Market cap
- $1.05B
- P/E (trailing)
- —
- P/E (forward)
- -8.66
- EPS (trailing)
- $-0.15
- Dividend yield
- —
- Beta
- 1.04
- Avg. volume
- 2.85M
How Lexicon Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Lexicon Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LXRXLexicon Pharmaceuticals Inc. Common Stock$1.52▼ 7.88%Market cap $1.05BP/E —$1.1$2.68
- OLMAOlema Pharmaceuticals Inc. Common Stock$6.58▼ 4.22%Market cap $1.03BP/E —$6.61$36.26
- PCRXPacira BioSciences Inc. Common Stock$36.34▲ 0.03%Market cap $1.02BP/E 98.88$18.8$36.46
- ANLAdlai Nortye Ltd. American Depositary Shares$11.03▼ 8.77%Market cap $1.01BP/E —$0.879$17.25
- GERNGeron Corporation Common Stock$1.17▼ 4.88%Market cap $1.01BP/E —$1.04$2.01
- JBIOJade Biosciences Inc. Common Stock$13.47▼ 2.11%Market cap $1.10BP/E —$8.36$28
- IVAInventiva S.A. American Depository Shares$2.94▼ 5.47%Market cap $1.10BP/E —$2.57$6.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LXRX Lexicon Pharmaceuticals Inc. Common Stock | $1.05B | — | $1.52 | ▼ 7.88% | $1.1$2.68 |
| OLMA Olema Pharmaceuticals Inc. Common Stock | $1.03B | — | $6.58 | ▼ 4.22% | $6.61$36.26 |
| PCRX Pacira BioSciences Inc. Common Stock | $1.02B | 98.88 | $36.34 | ▲ 0.03% | $18.8$36.46 |
| ANL Adlai Nortye Ltd. American Depositary Shares | $1.01B | — | $11.03 | ▼ 8.77% | $0.879$17.25 |
| GERN Geron Corporation Common Stock | $1.01B | — | $1.17 | ▼ 4.88% | $1.04$2.01 |
| JBIO Jade Biosciences Inc. Common Stock | $1.10B | — | $13.47 | ▼ 2.11% | $8.36$28 |
| IVA Inventiva S.A. American Depository Shares | $1.10B | — | $2.94 | ▼ 5.47% | $2.57$6.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcriptbenzinga · 10/6/2026
- Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete TranscriptBenzinga · 10/6/2026
- Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial ProgressYahoo · 10/2/2026
- Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And MoreSeekingAlpha · 9/30/2026
- Why Lexicon Pharmaceuticals Stock Popped by Almost 6% TodayYahoo · 9/28/2026
- Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCMYahoo · 9/28/2026
- This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayBenzinga · 9/28/2026
- Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8Benzinga · 9/28/2026
- LX-9211 Market Outlook 2026-2034 | Sales Forecast Highlights Emerging Commercial OpportunitiesYahoo · 9/25/2026
Insider Activity
Insider Actions →- Swain Judith L · June 3, 2026 · Option Exercise89.3K
- Diane E. Sullivan · June 3, 2026 · Option Exercise89.3K
- Cheung Ivan · June 3, 2026 · Option Exercise89.3K
- Sam L. Barker · June 3, 2026 · Option Exercise89.3K
- Philippe Amouyal · June 3, 2026 · Option Exercise89.3K
- SOBECKI CHRISTOPHER J · June 3, 2026 · Option Exercise89.3K
- DEBBANE RAYMOND · June 3, 2026 · Option Exercise89.3K
- Philippe Amouyal · May 1, 2026 · Grant43.5K
- Philippe Amouyal · May 1, 2026 · Grant35.7K
- Sam L. Barker · May 1, 2026 · Grant43.5K
- Sam L. Barker · May 1, 2026 · Grant35.7K
- Cheung Ivan · May 1, 2026 · Grant43.5K
- Cheung Ivan · May 1, 2026 · Grant35.7K
- Swain Judith L · May 1, 2026 · Grant43.5K
- Swain Judith L · May 1, 2026 · Grant35.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 323.18M
- Total value held
- $501.79M
- Institutional holders
- 132
- Unknown154.73M
- Unknown45.06M
- Unknown44.30M
- Unknown17.91M
- Unknown9.52M
- Unknown7.81M
- Unknown4.94M
- Unknown3.32M
- Unknown3.24M
- Unknown3.17M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Lexicon Reports Consistent Heart Failure Drug Data in New Analysis
Lexicon Pharmaceuticals announced new analysis from the SOLOIST-WHF trial showing its drug sotagliflozin produced consistent results in patients with worsening heart failure across different baseline blood pressure levels. This post hoc analysis reinforces findings from the original trial studying hospitalized heart failure patients. The company also confirmed participation in three upcoming investor conferences, a routine corporate engagement practice. The data announcement represents the substantive news for this period.
Lexicon Reports Consistent Heart Failure Drug Data in New Analysis. Lexicon Pharmaceuticals announced new analysis from the SOLOIST-WHF trial showing its drug sotagliflozin produced consistent results in patients with worsening heart failure across different baseline blood pressure levels. This post hoc analysis reinforces findings from the original trial studying hospitalized heart failure patients. The company also confirmed participation in three upcoming investor conferences, a routine corporate engagement practice. The data announcement represents the substantive news for this period.